ClinicalTrials.gg
RecruitingNCT07214493ADJUSTUpdated Nov 25, 2025

Study on a Prosthetic Foot With Adjustable Heel Height

An interventional study of Taleo Adjust and The usual participant's foot in Lower Limb Amputation Above Knee and Lower Limb Amputation Below Knee, sponsored by Otto Bock France SNC. Recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Otto Bock France SNC · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Most prosthetic feet have a fixed heel height, which requires users to always wear shoes with the same heel height. A fixed heel height is a significant constraint, whereas the ability to choose one's clothing freely is an important aspect of coping with a physical disability.

The Taleo Adjust is a prosthetic foot with a hydraulic ankle that allows the user to adjust the heel height from 0 to 7 cm, depending on the type of shoe worn.

This study aims to evaluate the impact of an adjustable-heel-height foot on physical appearance and participation.

Read the detailed description

The amputation or absence of a lower limb affects both mobility and appearance, which can lead to restrictions in social, family, and professional participation. The choice of prosthetic components aims to compensate as effectively as possible for the functional and physical disability, in line with the patient's expectations and life plan.

The prosthetic foot is a key component of the prosthesis. Most feet have a fixed heel height-most often around 10 to 15 mm-which requires users to always wear shoes with the same heel height, since prosthetic alignment, essential for harmonious and safe walking, is set accordingly.

A fixed heel height is a significant constraint for many users who wish to wear different types of shoes for aesthetic reasons (e.g., city shoes or pumps for work or going out; flip-flops or flat ballet flats in summer), for safety reasons (e.g., boots for motorcycling or gardening), or to be able to walk barefoot (e.g., at home). The ability to choose one's clothing freely is an important aspect of coping with a physical disability.

The Taleo Adjust is an energy-storing and energy-returning prosthetic foot with a hydraulic ankle that allows the user to adjust the heel height from 0 to 7 cm, depending on the type of shoe worn. Thanks to this articulation, prosthetic alignment is preserved and walking quality is not compromised.

This study aims to evaluate the impact of an adjustable-heel-height foot on physical appearance and participation.

02

Conditions studied

  • Lower Limb Amputation Above Knee
  • Lower Limb Amputation Below Knee

Keywords

  • Lower limb amputation
  • Prosthetic foot
  • Adjustable heel height
  • Hydraulic ankle
03

In context

Lead sponsor

Otto Bock France SNC is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient with a major lower limb amputation whose life project includes:
  • movement in buildings other than the home (ICF d4601),
  • movement outside the home and other buildings (ICF d4602),
  • and other specified activities related to movement in other various places (ICF d4608).
  • Patient who has been using an Enregy storage and Return (ESR) foot for at least 3 months
  • Patient who wishes to walk with shoes with different heel heights, and/or barefoot

Exclusion criteria

Exclusion Criteria:

  • Patient with a high impact level (e.g.: sport)
  • Patient with hip disarticulation or equivalent
  • Patient with an unstabilised residual limb and/or an unsuitable socket
  • Patient who cannot be fitted with a Taleo Adjust foot due to the technical characteristics of the product (user weight greater than 115kg; required foot size \<22 or >28; mounting height less than 118 mm)
  • Patient whose usual foot has a heel height adjustment system
  • Patient unavailable for the duration of the study and/or unable to understand the instructions and/or answer questionnaires in French
  • Patient already participating in another study
  • Patient in an emergency situation or pregnant woman
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Taleo Adjust foot then usual foot

    The participant is first fitted with the Taleo Adjust foot for 30 days, then is fitted with their usual foot for 30 days.

    Device: Taleo Adjust · Device: The usual participant's foot

  • Other
    Usual foot then taleo Adjust foot

    The participant is first fitted with their usual foot for 30 days, then fitted with the Taleo Adjust foot for 30 days

    Device: Taleo Adjust · Device: The usual participant's foot

Interventions

  • DeviceTaleo Adjust

    The Taleo Adjust foot is an energy-storage-and-return (ESR) prosthetic foot with a hydraulic ankle joint that allows an adjustable heel height from 0 to 7 cm.

  • DeviceThe usual participant's foot

    The usual foot of the participant is an Energy Storage and Return (ESR) prosthetic foot (no heel height adjustement)

06

What researchers measure

Primary outcomes

  1. Prosthetic Evaluation Questionnaire - Appearance scale (PEQ-AP)

    A 5-item self-reported measure of the appearance domain. The participant rates each item by marking a 100-mm line. Scores range from 0 to 100, with higher scores indicating a more positive perception.

    Time frame: 30 days

Secondary outcomes

  1. Patient Specific functional Scale (PSFS)

    A self-reported measure of participation based on 3 to 5 self-selected activities that the participant cannot perform or can perform only with difficulty. Participants will be asked to rate their ability to perform each activity on a numerical scale from 0 (unable to perform the activity) to 10 (able to fully perform the activity).

    Time frame: 30 days

  2. Psychosocial Impact of Assistive Device Scale (PIADS)

    A 26-item questionnaire that assesses the effects of an assistive device on functional independence, well-being, and quality of life from the perspective of the person's disability. Each item is rated on a 7-point Likert scale ranging from -3 (maximum negative impact) to +3 (maximum positive impact).

    Time frame: 30 days

  3. Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0)

    A 12-item self-reported measure of the participant's satisfaction with the device's technology and the services associated with it. An average satisfaction rating can be calculated on a scale from 1 to 5, with 1 = "Not at all satisfied" and 5 = "Very satisfied". A higher score indicates greater satisfaction. It also allows the participant to express the three criteria that are most important to them.

    Time frame: 30 days

  4. Visual Analog Scale (VAS) for the adequacy to life's project

    An 11-level numerical scale ranging from 0 (total dissatisfaction) to 10 (total satisfaction), measuring how well the device aligns with the participant's life project

    Time frame: 30 days

  5. EuroQuol - 5 Dimensions - 5 Levels (EQ-5D-5L)

    A self-reported measure of health status composed of five dimensions: mobility, self-care, ability to perform usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-point scale. A utility index, which is a single value derived from a patient's responses to these dimensions, can be calculated using a population-specific value set, typically ranging from 0 (death) to 1 (perfect health). Health status is also expressed using the EQ-VAS (Visual Analog Scale). The EQ-VAS records the patient's self-assessment of health on a vertical visual analog scale, ranging from 0 "The worst health you could imagine" to 100 "The best health you could imagine."

    Time frame: 30 days

  6. Prosthetic Limb Users Survey of Mobility (PLUS-M)

    A 12-items self-reported measure of mobility as the ability to move intentionally and independantly from one place to another. Questions cover movements that range from basic ambulation to complex activities . Response options going from 1 (unable to do) to 5 (without any difficulty), reflecting the degree of difficulty with which respondents report they can perform these activities. The PLUS-M™ 12-item short form provides a T-score ranging from 21.8 to 71.4, with higher scores indicating better mobility.

    Time frame: 30 days

  7. Socket Comfort Scale (SCS)

    A 11-levels numerical scale going from 0 (the most uncomfortable socket) to 10 (the most comfortable socket), measuring the perceived comfort in the socket.

    Time frame: 30 days

07

Study locations

5 of 5 sites recruiting
  • CH Cornouaille
    Concarneau, France
    Recruiting
  • CHU Grenoble
    Échirolles, France
    Recruiting
  • IRR Louis Pierquin
    Nancy, France
    Recruiting
  • CRRF La Tourmaline
    Saint-Herblain, France
    Recruiting
  • Institut Merle d'Aubigné
    Valenton, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jun 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Oct 9, 2025
StartActual
Oct 8, 2025
Primary completionEst.
Jun 6, 2026
CompletionEst.
Jun 6, 2026
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07214493
Lead sponsor
Otto Bock France SNC
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Oct 8, 2025
Primary completion
Jun 6, 2026 (estimated)
Completion
Jun 6, 2026 (estimated)
Last update
Nov 25, 2025

Study contacts

Aurelie LACROIX
Contact
aurelie.lacroix@ottobock.com
0033 (0)7 86 29 52 03
Brice LAVRARD, Dr.
study chair · Institut Merle d'Aubigné - VALENTON
Isabelle LOIRET
study chair · IRR Louis Pierquin - NANCY

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion